Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2005
10/20/2005WO2005097211A2 Compositions as adjuvants to improve immune responses to vaccines and methods of use
10/20/2005WO2005097210A1 Bioresponsive polymer system for delivery of microbicides
10/20/2005WO2005097203A2 Serum protein conjugates of ion channel modulating compounds and uses thereof
10/20/2005WO2005097202A2 Use of serum albumin binding peptides conjugates for the preparation of a medicament
10/20/2005WO2005097201A2 Inclusion complexes containing piroxicam, a cyclodextrin and arginine
10/20/2005WO2005097200A2 Tetanus toxin fusion protein for visualization of active synapses
10/20/2005WO2005097199A1 Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
10/20/2005WO2005097198A1 Preparation for oral administration
10/20/2005WO2005097197A1 Polymer particles containing active agents
10/20/2005WO2005097196A2 Pharmaceutical preparation containing drospirenone for application to the skin
10/20/2005WO2005097195A2 Methods of reducing aggregation of il-1ra
10/20/2005WO2005097194A1 Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof
10/20/2005WO2005097166A1 Remedy for diabetic neuropathy comprising gelatin gel as carrier
10/20/2005WO2005097152A1 Turmeric extract-containing composition having improved caking capacity
10/20/2005WO2005097144A1 Composition for cleaning intestinal canal
10/20/2005WO2005097120A1 Compositions with reduced hepatotoxicity
10/20/2005WO2005097105A1 Injectable composition for the treatment of cancers
10/20/2005WO2005097104A1 SOLID PHARMACEUTICAL PREPARATION CONTAINING DIBENZ[b,e]OXEPINE DERIVATIVE
10/20/2005WO2005097091A1 Composition comprising reduced-form coenzyme q10 and carotenoid compound
10/20/2005WO2005097087A2 Merged ion channel modulating compounds and uses thereof
10/20/2005WO2005097085A1 Nutrient system for individualized responsive dosing regimens
10/20/2005WO2005097081A1 Ion binding polymers and uses thereof
10/20/2005WO2005097073A1 Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
10/20/2005WO2005097072A1 Ion binding compositions
10/20/2005WO2005097070A1 Solid pharmaceutical preparation with improved stability and process for producing the same
10/20/2005WO2005097068A1 Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
10/20/2005WO2005097067A1 Zinc preservative composition and method of use
10/20/2005WO2005097058A2 Cyclodextrin inclusions complexes of pyrimidine-2,4,6-triones
10/20/2005WO2005097041A1 Nucleated molded article and method of producing the same
10/20/2005WO2005096789A2 Methods and compositions for imaging and biomedical applications
10/20/2005WO2005096717A2 Agent exhibiting hepatoprotective properties
10/20/2005WO2005084713A3 Enzyme-prodrug therapy for prosthetic joint repair
10/20/2005WO2005083431A3 Binding agents
10/20/2005WO2005074887A3 Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof
10/20/2005WO2005065708A3 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
10/20/2005WO2005053660A3 Pharmaceutical compositions comprising danazol
10/20/2005WO2005052006A3 Mutated anti-cd22 antibodies and immunoconjugates
10/20/2005WO2005049061A3 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
10/20/2005WO2005046729A3 Use of lipopeptides for activating t lymphocytes through the skin
10/20/2005WO2005044985A3 Delivery of polymer conjugates of therapeutic peptides and proteins via coated microporjections
10/20/2005WO2005027954A3 Sincalide formulations
10/20/2005WO2005016260A3 Prodrugs for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides
10/20/2005WO2004060405A3 Tissue reactive compounds and compositions and uses thereof
10/20/2005US20050234232 Novel compositions for the delivery of negatively charged molecules
10/20/2005US20050234230 formed via reductive amination with O-[2-(2-aminooxy-ethoxy)-ethyl]-hydroxyl amine; conjugated to erythropoietin
10/20/2005US20050234222 Polypeptide comprising at least one alpha-helix having synthetically attached thereto a plurality of therapeutic or diagnostic moieties
10/20/2005US20050234032 Antibacterial compositions comprising metal phthalocyanine analogues
10/20/2005US20050234028 solid dosage form for contraceptives and hormone replacement therapy; very low moisture content to prevent ester hydrolysis; enhanced bioavailability of 17-beta-estradiol
10/20/2005US20050234018 Drug delivery to the back of the eye
10/20/2005US20050234011 Re-epithelializing pharmaceutical compositions comprising xanthan gum
10/20/2005US20050233999 That contain unmethylated cytosine-guanine (CpG) dinucleotides; stimulate an immune response and to redirect a Th2 response to a Th1 response; use with vaccines
10/20/2005US20050233997 RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
10/20/2005US20050233995 Immunostimulatory nucleic acid molecules
10/20/2005US20050233990 Anti-cancer agents comprising disintegrin genes and the treating methods
10/20/2005US20050233968 Polyamino acid-based insulin preparation
10/20/2005US20050233949 Conjugates comprising cancer cell specific ligands, a sugar and cancer chemotherapeutic agents/boron neutron capture therapy agents, and uses thereof
10/20/2005US20050233948 Drug complex for treatment of metastatic prostate cancer
10/20/2005US20050233943 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
10/20/2005US20050233402 Heparinase III HLGAG fragments and uses thereof
10/20/2005US20050233385 Using antibodies on cell surfaces
10/20/2005US20050233344 RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
10/20/2005US20050233301 Cryopreservation of haptenized tumor cells
10/20/2005US20050233048 Edible film
10/20/2005US20050233003 Nanosized particles of salicylic acid wrapped in an amphiphilic polymer of polyacrylic acid, polyacrylamide, polymethacrylamide and polylysine; polymer is modified with urea, nicotinamide or guanidine
10/20/2005US20050233002 Encapsulation of oxygen sensitive agents
10/20/2005US20050233001 Particles of megestrol, megestrol acetate, and surface stabilizer; endometriosis, dysmenorrhea, hirsutism, uterine bleeding, neoplastic diseases, appetite enhancement, contraception
10/20/2005US20050232998 Dry powder inhalant composition
10/20/2005US20050232994 Dual-spike release formulation for oral drug delivery
10/20/2005US20050232989 Process for preparing oral calcium compositions
10/20/2005US20050232984 Non-vesicular cationic lipid formulations
10/20/2005US20050232982 drug layer, support layer insoluble in water comprising ethyl cellulose and hydroxypropyl methylcellulose, backing on support layer, wherein drug layer consists of fentanyl or salt as active ingredient, methyl vinyl ether-maleic anhydride copolymer as adhesive, hydroxypropylcellulose; easily removed
10/20/2005US20050232981 Compositions capable of facilitating penetration across a biological barrier
10/20/2005US20050232973 Systems and methods for preparation of pharmaceutical dosage using compositions containing aqueous vesicles
10/20/2005US20050232952 Self emulsifying drug delivery systems for poorly soluble drugs
10/20/2005US20050232928 Drug conjugates
10/20/2005US20050232924 Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
10/20/2005US20050232899 Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
10/20/2005US20050232898 Stabilized protein compositions
10/20/2005US20050232879 Antifungal medicinal compositions
10/20/2005US20050232872 Compositions and methods for enhancing receptor-mediated cellular internalization
10/20/2005US20050232870 Method of treatment of dopamine-related dysfunction
10/20/2005US20050232865 Microbubble-generating carbohydrate microparticles encapsulated in biodegradable, crosslinked protein shells for enhanced echocardiographic imaging
10/20/2005DE20221397U1 Transdermal-Pflaster zum Verabreichen von Fentanyl Transdermal patch for administering fentanyl
10/20/2005CA2829943A1 Ion binding compositions
10/20/2005CA2806465A1 Ion binding polymers and uses thereof
10/20/2005CA2563271A1 Solid products with improved stability and method for producing the same
10/20/2005CA2563101A1 Inclusion complexes obtained using a supercritical co2 process and an interaction agent with the compound
10/20/2005CA2562266A1 Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
10/20/2005CA2561918A1 Preparation for oral administration
10/20/2005CA2561619A1 Compositions with reduced hepatotoxicity
10/20/2005CA2561174A1 Bioresponsive polymer system for delivery of microbicides
10/20/2005CA2560941A1 Compositions as adjuvants to improve immune responses to vaccines and methods of use
10/20/2005CA2560724A1 Zinc preservative composition and method of use
10/20/2005CA2560312A1 Embolization
10/20/2005CA2558853A1 Polymer particles containing active agents
10/20/2005CA2558349A1 Pharmaceutical preparation containing drospirenone for application to the skin
10/20/2005CA2557848A1 Ion binding compositions
10/20/2005CA2557448A1 Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
10/19/2005EP1586582A1 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
10/19/2005EP1586557A1 4-nitro-2- (4 -methoxy)-phenoxy -methanesulfonanilide derivates and their pharmaceutical use
1 ... 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 ... 1712